Form 4: Alnylam CEO's Stock Transactions Post-Vesting

Alnylam Pharmaceuticals CEO Yvonne Greenstreet acquired shares from PSU vesting and sold a portion to cover tax obligations.

Summary

• Yvonne Greenstreet, Chief Executive Officer and Director of Alnylam Pharmaceuticals, Inc. (ALNY), reported changes in her beneficial ownership.
• On August 15, 2025, Ms. Greenstreet acquired 14,252 shares of common stock at $0.0 per share due to the vesting of performance-based stock units (PSUs) granted on March 1, 2024.
• The PSU vesting was triggered by the achievement of a specified clinical milestone, as determined by the Issuer's People, Culture and Compensation Committee.
• On August 18, 2025, she sold a total of 7,029 shares of common stock in multiple transactions at weighted average prices ranging from $447.98 to $455.82 per share.
• These sales were mandatory "sell-to-cover" transactions to satisfy minimum statutory tax withholding obligations upon the vesting and settlement of restricted stock units (RSUs) granted on March 1, 2024.
• Following these transactions, Ms. Greenstreet directly beneficially owns 56,221 shares of common stock and indirectly owns 407 shares through a managed 401(k) account.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions related to equity compensation. The vesting of performance-based units due to a clinical milestone is a positive operational indicator, while the sell-to-cover transactions are standard and expected for tax purposes, leading to a slightly positive but largely neutral sentiment.

Positives

• The vesting of 14,252 performance-based stock units (PSUs) indicates the achievement of a specified clinical milestone.
• The PSU vesting demonstrates successful execution against pre-defined performance measures, reflecting progress in the company's clinical development.

Negatives

• The sale of 7,029 shares was a mandatory "sell-to-cover" to meet tax obligations, not a discretionary sale by the insider, which is a routine event rather than a negative indicator of company performance.

Risks

• No specific risks related to the company's operations or financial health are disclosed in this Form 4 filing, as it primarily reports insider transactions.

Future Outlook

This Form 4 filing, which reports changes in beneficial ownership, does not contain any forward-looking statements or guidance regarding the company's future performance, strategic direction, or financial outlook.

Industry Context

Insider transactions, such as those reported in a Form 4, are common occurrences in publicly traded companies, particularly for executives receiving equity-based compensation. The "sell-to-cover" mechanism for tax obligations is a standard practice for vesting restricted stock units or performance-based awards in the pharmaceutical and biotechnology sectors, where equity compensation is a significant component of executive pay. The achievement of a clinical milestone, which triggered the PSU vesting, is a positive indicator within the biotech industry, signaling progress in drug development.

Comparison to Industry Standards

• Not applicable. This filing details routine insider transactions related to equity compensation and tax obligations, which are standard practices across industries and do not provide a basis for comparison to specific company or project results.

Related Party Transactions

• The transactions reported relate to the compensation of a key executive (Yvonne Greenstreet), which is a form of related party transaction. These are standard equity compensation arrangements.

Stakeholder Impact

• Shareholders: The vesting of performance-based units could be viewed positively as it indicates the achievement of a clinical milestone, potentially adding value. The sell-to-cover sales are routine and generally have minimal impact on share price or ownership structure.
• Employees: No direct impact on general employees is indicated.
• Customers: No direct impact on customers is indicated.
• Suppliers: No direct impact on suppliers is indicated.
• Creditors: No direct impact on creditors is indicated.

Next Steps

• No specific future actions, events, or milestones are mentioned in this Form 4 filing beyond the reported transactions.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to equity compensation, specifically the vesting of performance-based stock units due to a clinical milestone and subsequent mandatory sell-to-cover sales for tax obligations. While the clinical milestone achievement is a positive operational note, the transactions themselves are expected and do not provide new material information that would warrant a change in investment recommendation. The filing does not contain any insights into the company's financial performance, strategic direction, or competitive landscape that would influence a buy or sell decision. Therefore, a "hold" recommendation is appropriate as this filing does not alter the fundamental investment thesis for Alnylam Pharmaceuticals.

Keywords

Alnylam Pharmaceuticals, ALNY, Form 4, insider trading, stock vesting, CEO, Yvonne Greenstreet, equity compensation, sell-to-cover, performance-based stock units, restricted stock units, biotechnology, pharmaceuticals